株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

院内感染性肺炎(HAP):世界の治験レビュー

Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 321706
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.49円で換算しております。
Back to Top
院内感染性肺炎(HAP):世界の治験レビュー Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2017
出版日: 2017年09月22日 ページ情報: 英文 159 Pages
概要

当レポートでは、院内感染性肺炎(HAP)の臨床試験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、臨床試験を実施している主な製薬企業および研究機関のプロファイルなどをまとめています。

イントロダクション

  • 院内感染性肺炎(HAP)
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:感染症の治験における院内感染性肺炎(HAP)の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:感染症の治験における院内感染性肺炎(HAP)の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

院内感染性肺炎(HAP)治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • AstraZeneca PLC
    • Cubist Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Evolva Holding SA
    • Sanofi
    • KaloBios Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Janssen Pharmaceuticals, Inc.
    • Basilea Pharmaceutica AG
  • 代表的な研究機関・病院の治験の概要
    • University of Thessaly
    • Prince of Songkla University
    • Universite Victor Segalen Bordeaux 2
    • University of Athens
    • Denver Health and Hospital Authority
    • St. Joseph's Hospital and Medical Center
    • Mahidol University
    • Arak University of Medical Sciences
    • Hospital Pablo Tobon Uribe
    • Hamedan University of Medical Sciences

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC4596CTIDB

GlobalData's clinical trial report, "Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2017" provides an overview of Hospital Acquired Pneumonia (HAP) clinical trials scenario. This report provides top line data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 2
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Clinical Trial Profile Snapshots 31

Appendix 157

  • Abbreviations 157
  • Definitions 157
  • Research Methodology 158
  • Secondary Research 158
  • About GlobalData 159
  • Contact Us 159
  • Source 159

List of Tables

List of Tables

  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 158
Back to Top